미국의 갱년기 장애 시장 규모, 점유율, 동향 분석 리포트 : 치료별, 부문별 예측(2024-2030년)

U.S. Menopause Market Growth & Trends:

The U.S. menopause market size is anticipated to reach USD 7.3 billion by 2030, growing at a CAGR of 4.8% during the forecast period, according to a new report by Grand View Research, Inc. The rising aging women population worldwide reaching menopause and its related symptoms are resulting in a growing demand for menopause-related products, services, and treatments. In addition, the menopause market in the U.S. is expanding due to the rising inclination towards natural and organic menopause remedies. Furthermore, the market growth is also supported by the introduction of advanced products and technologies, such as hormone-free therapies and telemedicine services.

Lifestyle factors such as smoking, alcohol consumption, and obesity can exacerbate menopause symptoms, leading to an increased demand for menopause treatments. Women who lead unhealthy lifestyles are more likely to experience severe menopause symptoms, which is expected to drive the market's growth. According to a study published by the National Library of Medicine, the risk of frequent or severe vasomotor symptoms increased significantly among obese smokers.

There has been a growing focus on personalized medicine, with treatments tailored to each patient's individual needs However, several smaller companies specialize in niche areas of the market, such as alternative therapies or personalized medicine approaches. For instance, in March 2023, Blue Cross Blue Shield of Michigan and Blue Care Network introduced a women's health solution to aid their members in transitioning into menopause. A key feature of the Family Building and Women's Health Support Solution is a digital app that provides personalized care, helping members identify symptoms, explore treatment options, connect with experts, and join peer communities for support.

U.S. Menopause Market Report Highlights:

• Dietary supplements dominated the treatment segment with around 95% of the revenue share in 2023, owing to the increasing awareness, availability, and affordability of natural treatments and ingredients during the menopause stage
• Women are opting for non-hormonal treatments for menopause, such as herbal supplements, acupuncture, and cognitive-behavioral therapy, due to concerns about side effects and long-term health risks
• In January 2024, Dr. Reddy's Laboratories Ltd. acquired MenoLabs, a portfolio of dietary supplements for women's health, from Amyris, Inc. The U.S. Dr. Reddy's now owns all seven MenoLabs supplements, which are designed to help with symptoms of perimenopause and menopause, including probiotics like MenoGlow, MenoFit, and Happy Fiber.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Volume price analysis (Model 2)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Menopause Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Menopause Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Menopause Market: Treatment Estimates & Trend Analysis

• 4.1. Form Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. U.S. Menopause Market by Treatment Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Dietary Supplements
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. OTC Pharma Products
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.2. Hormonal
    • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.3. Non Hormonal
    • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Competitive Landscape

• 5.1. Recent Developments & Impact Analysis, By Key Market Participants
• 5.2. Company/Competition Categorization
• 5.3. Vendor Landscape
  • 5.3.1. List of key distributors and channel partners
  • 5.3.2. Key customers
  • 5.3.3. Key company heat map analysis, 2023
• 5.4. Company Profiles
  • 5.4.1. Pfizer Inc.
    • 5.4.1.1. Company overview
    • 5.4.1.2. Financial performance
    • 5.4.1.3. Product benchmarking
    • 5.4.1.4. Strategic initiatives
  • 5.4.2. Novo Nordisk A/S
    • 5.4.2.1. Company overview
    • 5.4.2.2. Financial performance
    • 5.4.2.3. Product benchmarking
    • 5.4.2.4. Strategic initiatives
  • 5.4.3. TherapeuticsMD
    • 5.4.3.1. Company overview
    • 5.4.3.2. Financial performance
    • 5.4.3.3. Product benchmarking
    • 5.4.3.4. Strategic initiatives
  • 5.4.4. Bayer AG
    • 5.4.4.1. Company overview
    • 5.4.4.2. Financial performance
    • 5.4.4.3. Product benchmarking
    • 5.4.4.4. Strategic initiatives
  • 5.4.5. AbbVie, Inc.
    • 5.4.5.1. Company overview
    • 5.4.5.2. Financial performance
    • 5.4.5.3. Product benchmarking
    • 5.4.5.4. Strategic initiatives
  • 5.4.6. Pure Encapsulations, LLC.
    • 5.4.6.1. Company overview
    • 5.4.6.2. Financial performance
    • 5.4.6.3. Product benchmarking
    • 5.4.6.4. Strategic initiatives
  • 5.4.7. PADAGIS LLC
    • 5.4.7.1. Company overview
    • 5.4.7.2. Financial performance
    • 5.4.7.3. Product benchmarking
    • 5.4.7.4. Strategic initiatives